Live Breaking News & Updates on Ian De Boer

Stay updated with breaking news from Ian de boer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Will Kidney Disease Patients Finally Receive New Drug Class?

Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change? ....

San Francisco , United States , Donalda Molony , Tazeenh Jafar , Diana Kwong , Drug Administration , Kidney Research Institute , University Of California , University Of Washington , Kidney Disease , Improving Global Outcomes , Gross Underuse , Medical School , Ian De Boer , Chi Yuan Hsu , Choosing Among Dapa , Chronic Renal Failure , Hronic Kidney Failure , Hronic Kidney Disease Ckd , Chronic Kidney Disease , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Renal Failure , Enal Insufficiency ,

FDA Panel Endorses Kidney Disease Drug for Serum Phosphorus Control

Advisors see need for alternatives, citing suboptimal efficacy and tolerance of approved options ....

United States , Julia Lewis , Thomas Cook , C Noel Bairey Merz , Scott Emerson , Los Angeles , Christopher Oconnor , Patrick Nachman , Bairey Merz , Sinai Medical Center , Renal Drugs Advisory Committee On , Vanderbilt Medical Center , University Of Wisconsin , University Of Washington Seattle , Vascular Institute In Falls Church , University Of Washington , University Of Pittsburgh , University Of Minnesota , Renal Drugs Advisory Committee , Cedars Sinai Medical Center , Ian De Boer , Washington Seattle , Christophero Connor , Inova Heart , Vascular Institute , Falls Church ,